


ANILINE-DERIVED LIGANDS FOR THE THYROID RECEPTORAbstract of the Disclosure

- 5 New thyroid receptor ligands are provided which have the general formula



in which:

- X is -O-, -S-, -CH<sub>2</sub>-, -CO-, or -NH-;
- 10 Y is -(CH<sub>2</sub>)<sub>n</sub>- where n is an integer from 1 to 5, or cis- or trans-ethylene;
- R<sub>1</sub> is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons;
- R<sub>2</sub> and R<sub>3</sub> are the same or different and are
- 15 hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 6 carbons, at least one of R<sub>2</sub> and R<sub>3</sub> being other than hydrogen;
- R<sub>4</sub> is hydrogen or lower alkyl;
- R<sub>5</sub> is hydrogen or lower alkyl;
- 20 R<sub>6</sub> is carboxylic acid, or esters or prodrugs;
- R<sub>7</sub> is hydrogen or an alkanoyl or an aroyl.

- In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the
- 25 expression of a T<sub>3</sub> regulated gene, wherein a compound as described above is administered in a therapeutically effective amount. Examples of such diseases associated with metabolism dysfunction or are dependent upon the expression of a T<sub>3</sub> regulated gene include obesity,
- 30 hypercholesterolemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer as well as glaucoma, congestive heart failure and skin disorders.